Investigational Drug Information for Entinostat
What is the drug development status for Entinostat?
Entinostat is an investigational drug.
There have been 73 clinical trials for Entinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 24th 2025.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Syndax Pharmaceuticals, and Merck Sharp & Dohme Corp.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Entinostat
| US Patents | 1,381 |
| International Patents | 4,881 |
| US Patent Applications | 3,838 |
| WIPO Patent Applications | 1,250 |
| Japanese Patent Applications | 321 |
| Clinical Trial Progress | Phase 2 (2025-11-24) |
| Vendors | 80 |
Recent Clinical Trials for Entinostat
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer | Sun Yat-sen University | PHASE2 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | PHASE1 |
| A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Prog | Zhejiang Cancer Hospital | PHASE2 |
Clinical Trial Summary for Entinostat
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
US Patents for Entinostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Entinostat | ⤷ Start Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Start Trial |
| Entinostat | ⤷ Start Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Start Trial |
| Entinostat | ⤷ Start Trial | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Entinostat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Entinostat | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Start Trial |
| Entinostat | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Start Trial |
| Entinostat | Spain | ES2823756 | 2034-04-16 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
